

%BF, Rather Than BMI, is Associated with an Increased Risk of Sarcopenia in Hospitalized Postmenopausal Chinese Women with Type 2 Diabetes Mellitus

Lanyu Lu¹*, Guohui Du²*, Chaogang Qi, Junru Liu, Xing Wang, Dongmei Fan, Lina Sun³, Ning Wang, Bowei Liu

Department of Endocrinology, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, People's Republic of China

*These authors contributed equally to this work

Correspondence: Bowei Liu, Department of Endocrinology, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, People's Republic of China, Tel +86-335-5908603, Email liubo_wei@126.com

Purpose: To investigate the relationship between obesity indices and sarcopenia in postmenopausal patients with type 2 diabetes mellitus (T2DM) at different body mass index (BMI) levels.

Patients and Methods: This retrospective cross-sectional study included 298 hospitalized postmenopausal women diagnosed with T2DM. We collected demographic, biochemical, and anthropometric data on each subject. Body composition was measured using dual-energy X-ray absorptiometry (DXA), and skeletal muscle mass index (SMI) and body fat percentage (%BF) were calculated. According to BMI stratification, the patients were divided into normal group A ($18.5 \text{ kg/m}^2 \leq \text{BMI} < 24 \text{ kg/m}^2$), overweight group B ($24.0 \text{ kg/m}^2 \leq \text{BMI} < 28 \text{ kg/m}^2$), and obesity group C ($28.0 \text{ kg/m}^2 \leq \text{BMI} < 35 \text{ kg/m}^2$).

Results: From group A to group C, SMI (5.21 ± 0.56 vs 5.48 ± 0.56 vs 6.03 ± 0.69) increased gradually ($P < 0.05$). Logistic regression analysis indicated that for each 1-unit increase in BMI, the risk of sarcopenia decreased by 63.2% ($\text{OR} = 0.368$, 95% CI 0.215–0.629, $P = 0.000$) in group A. Age ($\text{OR} = 1.077$, 95% CI 1.015–1.144, $P = 0.015$) and %BF ($\text{OR} = 1.094$, 95% CI 1.010–1.186, $P = 0.028$) increased the risk of sarcopenia by 1.077 and 1.094 times, respectively, in group B. While every 1-unit increase in BMI, the risk of sarcopenia decreased by 35% ($\text{OR} = 0.650$, 95% CI 0.430–0.983, $P = 0.041$) in group B. %BF ($\text{OR} = 1.459$, 95% CI 1.093–1.949, $P = 0.010$) increased the risk factors of sarcopenia by 1.459 times in group C.

Conclusion: In postmenopausal patients with T2DM, BMI had a protective effect on the occurrence of sarcopenia within a certain range, and with the increase of BMI, the risk of sarcopenia was increasing by increased %BF levels in overweight and obese patients.

Keywords: postmenopausal women, T2DM, sarcopenia, %BF, BMI

Introduction

The incidence of type 2 diabetes mellitus (T2DM) in China had been increasing year by year. Studies had shown that the prevalence of sarcopenia in T2DM patients had reached 28%.¹ Sarcopenia has recently been identified as a complication of T2DM.² It is characterized by a progressive reduction in skeletal muscle mass associated with aging, accompanied by muscle strength and/or muscle function decline syndrome, which could lead to an increase in a series of adverse consequences, such as falls, fractures, bed rest, readmission, death, etc.³ One of the metabolic complications caused by obesity was diabetes.⁴ Adipose tissue played a key role in the development of insulin resistance,⁵ and the increase of intermuscular fat (IMAT) puts the skeletal muscle system in a low-grade inflammation,⁶ thus promoting the occurrence of sarcopenia. It could be seen that obesity, diabetes, and sarcopenia were inextricably linked.

In recent years, sarcopenic obesity had received increasing attention in the industry, characterized by low muscle mass and high body fat, with an increasing prevalence with age,⁷ which was associated with an increased risk of cardiovascular disease, metabolic disorders, cognitive impairment, arthritis, functional limitations, and lung disease.⁸ And elderly patients were more common to experience a decrease in lean body mass due to excessive obesity. Therefore, sarcopenia often coexisted with overweight and obesity in the elderly population.⁹ Although the international guideline consensus was to use body mass index (BMI) as a diagnostic indicator of overweight and obesity, BMI could not well interpret the body composition of fat mass and lean body mass in overweight and obese patients, especially the impact of BMI as an evaluation indicator of obesity on sarcopenia was still controversial. Recent studies indicate that overweight and obesity, as defined by BMI, may have a protective effect against sarcopenia in specific populations, though this relationship is still subject to debate.¹⁰ Lu et al also found that overweight or obesity as defined by BMI could prevent sarcopenia.¹¹ It had also been reported that the increase of BMI was accompanied by the increase of body fat and the decrease of muscle mass, which increased the risk of sarcopenia.¹²

Different obesity parameter indicators were often used in clinical and scientific research to evaluate the risk and prognosis of related diseases. Common obesity indices included BMI, waist circumference (WC), waist to height ratio (WHtR), and body fat rate (%BF). In recent years, new obesity indices had also included visceral adiposity index (VAI) and lipid accumulation product (LAP).^{13,14} The emergence of these obesity assessment indicators enriched the role of BMI, which previously relied solely on weight and height and could not distinguish body composition, in the diagnosis and prognosis of diseases. The introduction of abdominal obesity assessment indicators further approached the application of body composition assessment in obesity assessment.¹⁵

Compared to obesity, abdominal obesity was more prominent in Chinese T2DM patients.^{16,17} BMI and other obesity evaluation indicators, which was more closely related to sarcopenia? Therefore, our study chose the special population of postmenopausal women, as their sudden decrease in estrogen levels and redistribution of fat increased the risk of T2DM and sarcopenia.^{18,19} The aim of this study was to explore the relationship between different obesity indices and sarcopenia and its parameters in postmenopausal T2DM patients at different BMI levels, in order to seek more meaningful obesity indices to improve the early identification and prevention of sarcopenia in postmenopausal T2DM, a special group prone to sarcopenia.

Materials and Methods

Subjects

By using a retrospective cross-sectional study design, 298 postmenopausal inpatients diagnosed with T2DM in the Department of Endocrinology, the First Hospital of Qinhuangdao of Hebei from September 2019 to June 2023, were selected. The exclusion criteria included the following: 1) acute complications of diabetes mellitus such as diabetic ketoacidosis and hyperosmolar hyperglycemia; 2) acute myocardial infarction; acute cerebrovascular disease; acute inflammation; Gastrointestinal bleeding; Malignant tumor; 3) maintenance hemodialysis; 4) hepatic dysfunction (>3-fold elevation of alanine aminotransferase, aspartate aminotransferase); 5) severe osteoarthropathy or neuromuscular disease; 6) implantation of a pacemaker; 7) inability to understand/perform the exercise tests for this study. This study was approved by the Ethics Committee of the First Hospital of Qinhuangdao (Approval number: No.2020B004) in accordance with the ethical principles of the Declaration of Helsinki. All patients provided written informed consent for participation.

Data Collection

A pre-designed questionnaire was used to collect general data such as age and gender of the subjects, and anthropometric measurements were measured and recorded, including height, weight, calculated BMI ($\text{BMI} = \text{weight (kg)} / \text{height}^2 \text{ (m}^2\text{)}$), WC, and calculated WHtR ($\text{WHtR} = \text{WC(m)} / \text{height(m)}$). We measured grip strength with the Jamar dynamometer (Performance health supply, inc., Cedarburg, WI, USA). Subjects initially sat in a chair to maintain upper body straight, elbow bending 90°, with both hands or dominant hand to squeeze the dynamometer for 3 s. Subjects were asked to squeeze twice, taking the maximum as the final figure. A commonly used gait speed test is called the 6-m usual walking

speed test (6MWT), with speed measured manually with a stopwatch. Peripheral venous blood samples were taken at 8:00 AM after at least 8-hours of fasting and subjected to biochemical measurements, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), uric acid (UA), fasting blood glucose (FBG), and glycated hemoglobin (HbA1c). Body composition including total body fat and total body lean was assessed using dual-energy X-ray absorptiometry (DXA) (MEDILINK SARL., France), and skeletal muscle mass index (SMI) and body fat percentage (%BF) were subsequently calculated. (SMI = the sum of the lean amount of the bilateral upper limbs and the bilateral lower limbs (kg)/height² (m²); %BF = total body fat mass (TFM) (kg)/weight (kg) *100%). The visceral fat index (VAI) and lipid accumulation product (LAP) were calculated using relevant anthropometric and biochemical measurements.¹⁸ Calculation formula of VAI was shown:

$$VAI = \left(\frac{WC(cm)}{36.58 + (1.89 \times BMI)} \times \frac{TG(mmol/l)}{0.81} \times \frac{1.52}{HDL(mmol/l)} \right) \text{ in females.}^{18}$$

Calculation formula of LAP was shown:

$$LAP = (WC(cm) - 58) \times TG(mmol/l) \text{ in females.}^{18}$$

Diagnosis and Groups

The cut-off points of BMI were recommended by the Working Group on Obesity in China.²⁰ The people were divided into three groups according to BMI: normal group A (18.5 kg/m² ≤ BMI < 24 kg/m², n=101, 33.9%); overweight group B (24.0 kg/m² ≤ BMI < 28 kg/m², n=141, 47.3%); and obesity group C (28.0 kg/m² ≤ BMI < 35 kg/m², n=56, 18.8%). According to the recommended diagnostic algorithm of the Asian Working Group for Sarcopenia 2019 consensus (AWGS 2019).²¹ Sarcopenia was defined as low SMI (<5.4 kg/m² in females) associated with either low handgrip strength (HGS) (<18 kg in females) or low gait speed (<1.0 m/s). The subjects were divided into sarcopenia group (SP group: n = 100, 33.6%) and non-sarcopenia group (non-SP group, n = 198, 66.4%).

Statistical Analysis

Data were analyzed using SPSS (version 25.0 for Windows, SPSS Inc., Chicago, IL, USA). Baseline characteristics of the study participants are presented below. Continuous variables were expressed as mean (SD). Comparisons were conducted from different groups using Two-way ANOVA. We utilized Spearman correlation analysis to investigate the correlation between obesity indices and various parameters of sarcopenia at different BMI categories. Multivariate logistic regression analysis was performed to determine independent risk factors of sarcopenia in postmenopausal women with T2DM at different BMI levels. Statistical significance was established at $p < 0.05$.

Results

Comparison of Baseline Characteristics of Hospitalized Postmenopausal Women with T2DM Between SP Group and Non-SP Group

Compared with the non-SP group, the age of the SP group was significantly higher than that of the non-SP group, and UA, weight, height, BMI, WC, WHtR, LAP, HGS, 6MWT and SMI were lower than those of the non-SP group, with statistical significance ($P < 0.05$), [Table 1](#).

Comparison of Obesity Indices in Different BMI Categories

From group A to group C, WC, WHtR, LAP, and %BF were gradually increased among the three groups, and the differences were statistically significant ($P < 0.05$). There was no significant difference in VAI among the three groups ($P > 0.05$), as shown in [Table 2](#).

Table 1 Comparison of Baseline Characteristics of Hospitalized Postmenopausal Women with T2DM Between SP Group and Non-SP Group

	SP Group (n=100)	Non-SP Group (n=198)	t	P
Age (years)	67.32±7.61	63.23±7.86	-4.284	0.000*
HbA1c (%)	8.90±1.98	8.77±2.05	-0.492	0.623
FPG (mmol/L)	8.67±3.64	8.75±3.36	0.205	0.838
UA (mmol/L)	286.5±82.60	309.±84.47	2.213	0.028*
TG (mmol/L)	1.92±1.04	2.19±1.71	1.441	0.151
TC (mmol/L)	5.26±1.69	5.61±1.32	1.946	0.053
HDL-C (mmol/L)	1.10±0.28	1.13±0.39	0.704	0.482
LDL-C (mmol/L)	2.85±1.15	3.04±0.86	1.618	0.107
Weight (kg)	60.83±7.73	67.13±9.06	5.940	0.000*
Height (m)	1.58±0.05	1.59±0.05	2.073	0.039*
BMI (kg/ m ²)	24.25±2.90	26.31±3.37	5.233	0.000*
WC (cm)	88.37±8.40	91.46±8.66	2.940	0.004*
WtHR (%)	55.86±5.64	57.33±5.81	2.084	0.038*
%BF (%)	54.53±7.09	54.40±6.22	-0.162	0.872
VAI	3.83±2.69	4.25±4.31	0.896	0.371
LAP	59.49±37.18	73.9±61.42	2.158	0.032*
HGS (kg)	16.64±4.74	20.87±5.40	6.644	0.000*
6MWT (m/s)	0.87±0.15	1.00±0.21	5.840	0.000*

Notes: Values are expressed as means ± SD. SP group (sarcopenia group, n = 100) and non-SP group (non- sarcopenia group, n = 198).

Abbreviations: SP group, sarcopenia group; non-SP group, non- sarcopenia group; HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; UA, uric acid; TG, triglycerides; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; BMI, body mass index; WC, waist circumference; WtHR, waist to height ratio; %BF, body fat rate; VAI, visceral adiposity index; LAP, lipid accumulation product; HGS, handgrip strength; 6MWT, the 6-m usual walking speed test. SD, standard deviation. *P <0.05.

Table 2 Comparison of Obesity Indices in Different BMI Categories

	Group A (n=101)	Group B (n=141)	Group C (n=56)	F	p
WC (cm)	84.35±7.07♦*	90.83±6.04*	100.36±7.45	104.058	0.000
WtHR (%)	52.96±4.38♦*	56.98±4.28*	63.47±5.18	98.647	0.000
%BF (%)	51.32±6.42♦*	54.82±5.24*	59.14±6.60	31.909	0.000
VAI	3.44±2.82	4.44±4.74	4.49±2.59	2.362	0.096
LAP	47.45±33.85♦*	74.63±64.12*	94.01±46.13	15.833	0.000

Notes: Values are expressed as means ± SD. Group A: (normal; n=101); Group B: (overweight; n=141); Group C: (obesity; n=56). ♦compared with group B; *compared with group C.

Abbreviations: WC, waist circumference; WtHR, waist to height ratio; %BF, body fat rate; VAI, visceral adiposity index; LAP, lipid accumulation product. SD, standard deviation.

Spearman Correlation Analysis of Sarcopenia Parameters and Obesity Indices in Different BMI Categories

In the whole sample, SMI was positively correlated with BMI, WC, WtHR, VAI and LAP, the difference was statistically significant ($P < 0.05$). There was no significant correlation between HGS and obesity indices ($P > 0.05$). The 6MWT was negatively correlated with WC and WtHR, and the difference was statistically significant ($P < 0.05$), [Table 3](#).

In normal group A, SMI was positively correlated with BMI and negatively correlated with %BF, the difference was statistically significant ($P < 0.05$). There was no significant correlation between HGS and obesity indices ($P > 0.05$). The 6MWT was negatively correlated with WC and WtHR, and the difference was statistically significant ($P < 0.05$), [Table 3](#).

Table 3 Spearman Correlation Analysis of Sarcopenia Parameters and Obesity Indices in Different BMI Categories

		BMI (kg/ m ²)		WC (cm)		WHtR (%)		VAI		LAP		%BF (%)	
		<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>
The total sample	SMI	0.470	0.000	0.294	0.000	0.235	0.000	0.121	0.037	0.201	0.000	−0.103	0.076
	HGS	0.090	0.122	0.049	0.403	−0.050	0.385	−0.017	0.766	0.016	0.780	0.029	0.624
	6MWT	−0.095	0.101	−0.203	0.000	−0.250	0.000	0.024	0.678	−0.023	0.696	0.011	0.850
Group A	SMI	0.387	0.000	0.090	0.370	0.075	0.457	−0.028	0.785	−0.005	0.956	−0.298	0.002
	HGS	0.151	0.132	0.078	0.440	0.008	0.940	−0.152	0.129	−0.072	0.476	0.057	0.570
	6MWT	0.034	0.739	−0.347	0.000	−0.349	0.000	−0.066	0.510	−0.185	0.064	0.049	0.630
Group B	SMI	0.193	0.022	0.006	0.943	−0.112	0.188	0.197	0.019	0.180	0.033	−0.377	0.000
	HGS	0.166	0.049	0.047	0.577	−0.104	0.221	0.067	0.432	0.080	0.349	−0.023	0.785
	6MWT	0.087	0.305	−0.069	0.416	−0.148	0.080	0.079	0.352	0.087	0.307	0.073	0.390
Group C	SMI	0.115	0.397	−0.052	0.704	−0.135	0.322	−0.089	0.513	−0.067	0.622	−0.382	0.004
	HGS	−0.186	0.169	−0.244	0.070	−0.398	0.002	−0.171	0.207	−0.198	0.143	−0.079	0.565
	6MWT	−0.239	0.076	−0.205	0.130	−0.336	0.011	0.016	0.906	−0.050	0.717	0.015	0.910

Notes: the total sample: (n=298); Group A: (normal; n=101); Group B: (overweight; n=141); Group C: (obesity; n=56).

Abbreviations: BMI, body mass index; WC, waist circumference; WHtR, waist to height ratio; VAI, visceral adiposity index; LAP, lipid accumulation product; %BF, body fat rate; SMI, skeletal muscle mass index; HGS, handgrip strength; 6MWT, the 6-m usual walking speed test.

In the overweight group B, SMI was weak positively correlated with BMI, VAI and LAP, and negatively correlated with %BF, with statistical significance ($P < 0.05$). There was no correlation between HGS and 6MWT and obesity indices, with no statistical significance ($P > 0.05$), [Table 3](#).

In the obesity group C, SMI was negatively correlated with %BF; WHtR was negatively correlated with HGS and 6MWT, and the difference was statistically significant ($P < 0.05$), as shown in [Table 3](#).

Logistic Regression Analysis of Sarcopenia Risk Factors Across BMI Categories

In the overall study sample, whether it was sarcopenia (non-SP=0, SP=1) was the dependent variable, and age, BMI, WC, WHtR, %BF, LAP, and UA were the independent variables. Logistic regression analysis showed that: Age (OR=1.065, 95% CI 1.026–1.104, $P=0.001$), WHtR (OR=1.166, 95% CI 1.002–1.358, $P=0.047$), %BF (OR=1.060, 95% CI 1.011–1.113, $P=0.017$) was risk factors for sarcopenia. For every 1 unit increase in BMI, the risk of sarcopenia decreased by 26.4% (OR=0.736, 95% CI 0.635–0.853, $P=0.000$). Logistic analysis showed that each 1-unit increase in BMI decreased the risk of sarcopenia by 63.2% (OR=0.368, 95% CI 0.215–0.629, $P=0.000$) in group A. Age (OR=1.077, 95% CI 1.015–1.144, $P=0.015$) and %BF (OR=1.094, 95% CI 1.010–1.186, $P=0.028$) increased the risk of sarcopenia by 1.077 and 1.094 times, respectively, in group B. While each 1-unit increase in BMI, the risk of sarcopenia decreased by 35% (OR=0.650, 95% CI 0.430–0.983, $P=0.041$) in group B. %BF (OR=1.459, 95% CI 1.093–1.949, $P=0.010$) increased the risk factors of sarcopenia by 1.459 times in group C, as shown in [Table 4](#).

Discussion

T2DM and sarcopenia were both age-related diseases.²² Skeletal muscle was not only an athletic organ but also an endocrine and metabolic organ, which was responsible for about 80% of postprandial glucose utilization and played an important role in the regulation of glucose metabolism.²³ Sarcopenia had a complex etiology, the current etiological mechanisms of sarcopenia mainly focused on low grade chronic inflammation, insulin and anabolic resistance, mitochondrial dysfunction, oxidative stress, hormonal changes, malnutrition, inactivity, and chronic diseases.²⁴ The occurrence of sarcopenia was not only a part of aging but also strongly associated with obesity, insulin resistance, and T2DM.²⁵

Postmenopausal women, a special population, were selected as the research object in our study, which was characterized by a sudden drop in estrogen levels. And estrogen plays a crucial role in human physiology, including

Table 4 Logistic Regression Analysis of Sarcopenia Risk Factors Across BMI Categories

		B	OR	95% CI	P
The total sample (n=298)	Age (years)	0.063	1.065	1.026–1.104	0.001
	BMI (kg/ m ²)	−0.306	0.736	0.635–0.853	0.000
	WHtR (%)	0.154	1.166	1.002–1.358	0.047
	%BF (%)	0.059	1.060	1.011–1.113	0.017
Group A (n=101)	BMI (kg/ m ²)	−1.001	0.368	0.215–0.629	0.000
Group B (n=141)	Age (years)	0.074	1.077	1.015–1.144	0.015
	BMI (kg/ m ²)	−0.431	0.650	0.430–0.983	0.041
	%BF (%)	0.090	1.094	1.010–1.186	0.028
Group C (n=56)	%BF (%)	0.378	1.459	1.093–1.949	0.010

Notes: The dependent variable: sarcopenia (non-SP =0, SP =1). The independent variables: age, BMI, WC, WHtR, %BF, LAP and UA.

Abbreviations: BMI, body mass index; WC, waist circumference; WHtR, waist to height ratio; %BF, body fat rate; LAP, lipid accumulation product; UA, uric acid.

glucose and lipid metabolism, bone metabolism, reproductive function and nervous function.⁸ The decrease of circulating estrogen level directly or indirectly affects skeletal muscle mass and function, and accelerates the occurrence of sarcopenia.^{26,27} At the same time, with the increase of age, the distribution of body fat also changes, and visceral obesity is obvious, and the proportion of muscle decreases year by year. Previous studies had shown that over the age of 50, leg muscle mass and strength declined by 1%–2% and 1.5–5% per year, respectively.²⁸ In our study of postmenopausal hospitalized T2DM patients, we found that the detection rate of sarcopenia was 33.6%, slightly higher than the prevalence of sarcopenia in T2DM patients reported in previous studies of 30.06%,²⁹ and significantly higher than the prevalence of sarcopenia in Chinese community population of 19.6%.³⁰ The reason was that the special population in our study had diabetes and postmenopausal estrogen decline at the same time, which affected fat distribution, lipid metabolism disorder and insulin's effect on anabolism.

Sarcopenic obesity has also been a hot topic in recent years. Previous studies had shown that the increase of BMI could effectively reduce the incidence of sarcopenia.³⁰ Subjects with a high BMI tended to have more lean body mass, regardless of body fat. A Chinese cohort study found a protective effect of high BMI against sarcopenia in elderly people after a 4-year follow-up.³¹ Li conducted aerobic and strength training for 12 weeks on elderly people with sarcopenia obesity, which significantly reduced body fat, increased muscle mass, and improved physical function,³² indicating that increased BMI and increased skeletal muscle mass might be more favorable factors for maintaining and improving physical function and reducing the risk of sarcopenia in elderly people.

However, it had been suggested that although BMI has been the most important indicator of evaluating obesity, it was the sum of fat mass and lean body mass, and might not be the best indicator of evaluating the relationship between obesity and sarcopenia.⁹ Ectopic deposition of fat played a key role in the development of sarcopenia as well as a key factor in the poor prognosis of obesity.³³ A previous study in Australia found that the increase of BMI reflected a substantial increase in body fat mass and a decline in lean body mass, which may have adverse implications for future development of sarcopenia.¹² Cheng Li et al found that high visceral fat area could weaken the negative correlation between high BMI and sarcopenia.³⁴

Our study circumvented the inconsistency between BMI and lean body mass by stratification of BMI. This study found that the BMI and abdominal obesity evaluation indicators WC and WHtR of postmenopausal T2DM patients with sarcopenia were significantly lower than those of non-sarcopenia patients, while there was no difference in %BF, suggested that postmenopausal T2DM patients with sarcopenia had a relatively higher %BF regardless of whether they were overweight and obese. Spearman correlation analysis showed that the negative correlation between SMI and %BF gradually increased with the increase of BMI, and there was no significant relationship between BMI and SMI in

obese people. It can be seen that obesity defined by BMI does not mean that the larger the BMI, the larger the SMI. There was no significant correlation between grip strength and obesity indices in normal weight and overweight people. While in obese people, grip strength and gait speed, which represent muscle function indicators, were significantly negatively correlated with abdominal obesity indices WHtR. At the same time, our study also found that VAT and LAP, which represent the new obesity indices of visceral fat, had a weak positive correlation with SMI in overweight. A similar positive correlation between increased visceral fat and sarcopenia had also been reported.^{34,35} The possible reason was that adipose tissue was the main site of sex hormone storage and metabolism, and female abdominal fat stored high levels of sex hormones, which had a positive impact on skeletal muscle mass.³⁶ Therefore, different obesity phenotypes might have different effects on muscle mass and muscle function.

Logistic analysis of our study further confirmed that as BMI increased in postmenopausal T2DM patients, the protective effect of BMI on sarcopenia diminished, particularly in obese individuals, suggesting that the protective effect of BMI on the occurrence of sarcopenia appears within a certain range. Notably, %BF emerged as a significant risk factor for sarcopenia. Our study found that with the increase of BMI, especially in overweight and obese patients, %BF increased the risk of sarcopenia by 1.094 and 1.459 times, respectively. The possible mechanism was that in the normal progression of obesity, high BMI was usually accompanied by an increase in fat mass. In particular, the accumulation of visceral fat could cause systemic inflammatory response and insulin resistance, and then lead to skeletal muscle dysfunction and sarcopenia.³⁷ The adipose tissue of obese individuals had high levels of tumor necrosis factor- α (TNF- α), which promoted the production and secretion of several cellular inflammatory factors.³⁸ From the perspective of inflammation theory, fat tissue released large amounts of Interleukin-6 (IL-6) and TNF- α , leading to low-level chronic inflammation, reducing insulin sensitivity, impacting protein synthesis ability, promoting hydrolytic metabolic pathways, and ultimately damaging muscle function. The amount of fat increases with age and could gradually penetrate into skeletal muscle, resulting in changes in muscle fiber structure and contractile performance, resulting in loss of skeletal muscle mass, strength, and function.³⁹

The present study also had some limitations. First, this study was a cross-sectional retrospective study, which precluded the establishment of causal relationships between events. Second, this study was a single-center study with a small sample size. Meanwhile, this study was limited to hospitalized postmenopausal T2DM patients, and no healthy people were collected as the control group. Therefore, the results need to be verified in multiple centers.

Conclusion

In postmenopausal women with T2DM, BMI exhibited a protective effect against sarcopenia within a specific range, although this protective effect diminishes as BMI increases, especially in the presence of high body fat percentage. However, the increasing %BF in overweight and obese individuals highlights the importance of comprehensive body composition assessments in early sarcopenia detection and prevention.

Acknowledgments

This work was supported by the People's Livelihood Special Project of Science and Technology Department of Hebei Province (2037708D).

Disclosure

The authors state that there are no conflict of interest in the publication of this article.

References

1. Fung FY, Koh YLE, Malhotra R, et al. Prevalence of and factors associated with sarcopenia among multi-ethnic ambulatory older Asians with type 2 diabetes mellitus in a primary care setting. *BMC Geriatr*. 2019;19(1):122. PMID: 31035928; PMCID: PMC6489356. doi:10.1186/s12877-019-1137-8
2. Izzo A, Massimino E, Riccardi G, Della Pepa G. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. *Nutrients*. 2021;13(1):183. PMID: 33435310; PMCID: PMC7826709. doi:10.3390/nu13010183
3. Cao Y, Li Y, Han W, et al. Sodium butyrate ameliorates type 2 diabetes-related sarcopenia through IL-33-independent ILC2s/IL-13/STAT3 signaling pathway. *J Inflamm Res*. 2023;16:343–358. PMID: 36733489; PMCID: PMC9888475. doi:10.2147/JIR.S392350

4. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. *Lancet*. 2022;399(10322):394–405. PMID: 34600604. doi:10.1016/S0140-6736(21)01919-X
5. James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. *Nat Rev Mol Cell Biol*. 2021;22(11):751–771. PMID: 34285405. doi:10.1038/s41580-021-00390-6
6. De Carvalho FG, Justice JN, Freitas EC, Kershaw EE, Sparks LM. Adipose tissue quality in aging: how structural and functional aspects of adipose tissue impact skeletal muscle quality. *Nutrients*. 2019;11(11):2553. PMID: 31652734; PMCID: PMC6893709. doi:10.3390/nu11112553
7. Ghiotto L, Muollo V, Tatangelo T, Schena F, Rossi AP. Exercise and physical performance in older adults with sarcopenic obesity: a systematic review. *Front Endocrinol*. 2022;13:913953. PMID: 35966077; PMCID: PMC9366852. doi:10.3389/fendo.2022.913953
8. Liu C, Wong PY, Chung YL, et al. Central versus peripheral impact of estradiol on the impaired glucose metabolism in ovariectomized mice on a high-fat diet. A systematic review and meta-analysis of sarcopenic obesity. *Obes Rev*. 2023;24(2):e13534. PMID: 36443946. doi:10.1111/obr.13534
9. Wannamethee SG, Atkins JL. Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. *Proc Nutr Soc*. 2015;74(4):405–412. PMID: 25913270. doi:10.1017/S002966511500169X
10. Merchant RA, Seetharaman S, Au L, et al. Relationship of fat mass index and fat free mass index with body mass index and association with function, cognition and sarcopenia in pre-frail older adults. *Front Endocrinol*. 2021;12:765415. PMID: 35002957; PMCID: PMC8741276. doi:10.3389/fendo.2021.765415
11. Lu L, Liu B, Ma Y. Association of different obesity phenotypes with sarcopenia in han Chinese middle-aged and elderly with type 2 diabetes individuals. *Diabetes Metab Syndr Obes*. 2023;16:841–848. PMID: 36974328; PMCID: PMC10039658. doi:10.2147/DMSO.S398475
12. Pasco JA, Gould H, Brennan SL, Nicholson GC, Kotowicz MA. Musculoskeletal deterioration in men accompanies increases in body fat. *Obesity*. 2014;22(3):863–867. PMID: 23625641. doi:10.1002/oby.20496
13. Zhang X, Sun Y, Li Y, et al. Association between visceral adiposity index and heart failure: a cross-sectional study. *Clin Cardiol*. 2023;46(3):310–319. PMID: 36651220; PMCID: PMC10018101. doi:10.1002/clc.23976
14. Ebrahimi M, Seyedi SA, Nabipoorashrafi SA, et al. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. *Lipids Health Dis*. 2023;22(1):41. PMID: 36922815; PMCID: PMC10015691. doi:10.1186/s12944-023-01802-6
15. Bagheri A, Khosravy T, Moradinazar M, et al. Optimal cut-off points of fat mass index and visceral adiposity index associated with type 2 diabetes mellitus. *Food Sci Nutr*. 2022;10(8):2710–2717. PMID: 35959273; PMCID: PMC9361442. doi:10.1002/fsn3.2874
16. Luo A, Tang Z, Xu X, et al. Cutoffs of different body measurement indexes of central obesity in patients with type 2 diabetes. *Sci Rep*. 2024;14(1):2154. PMID: 38273013; PMCID: PMC10811333. doi:10.1038/s41598-024-52645-9
17. Yi Q, Wu J, Shen Y, et al. Associations of concurrent early-life famine exposure and adulthood obesity with type 2 diabetes mellitus in middle-aged Chinese. *J Diabetes*. 2024;16(2):e13480. PMID: 37882478; PMCID: PMC10859315. doi:10.1111/1753-0407.13480
18. Raman V, Kose V, Somalwar S, Dwidmuthe KS, Rao S. Prevalence of metabolic syndrome and its association with menopausal symptoms in post-menopausal women: a scoping review. *Cureus*. 2023;15(5):e39069. PMID: 37323357; PMCID: PMC10267665. doi:10.7759/cureus.39069
19. Sipilä S, Törmäkangas T, Sillanpää E, et al. Muscle and bone mass in middle-aged women: role of menopausal status and physical activity. *J Cachexia Sarcopenia Muscle*. 2020;11(3):698–709. PMID: 32017473; PMCID: PMC7296268. doi:10.1002/jcsm.12547
20. Zhou BF; Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults—study on optimal cut-off points of body mass index and waist circumference in Chinese adults. *Biomed Environ Sci*. 2002;15(1):83–96. PMID: 12046553.
21. Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. *J Am Med Dir Assoc*. 2020;21(3):300–307.e2. PMID: 32033882. doi:10.1016/j.jamda.2019.12.012
22. Kurmaev DP, Bulgakova SV, Treneva EV, Chetverikova IS, Bashinskaya SA. [Sarcopenia and type 2 diabetes mellitus in geriatric patients (literature review)]. *Adv Gerontol*. 2022;35(6):818–826. PMID: 36905583.
23. DeFronzo RA, Gunnarsson R, Björkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. *J Clin Invest*. 1985;76(1):149–155. PMID: 3894418; PMCID: PMC423730. doi:10.1172/JCI111938
24. Granic A, Sayer AA, Robinson SM. Dietary patterns, skeletal muscle health, and sarcopenia in older adults. *Nutrients*. 2019;11(4):745. PMID: 30935012; PMCID: PMC6521630. doi:10.3390/nu11040745
25. Kitada M, Koya D. Autophagy in metabolic disease and ageing. *Nat Rev Endocrinol*. 2021;17(11):647–661. PMID: 34508250. doi:10.1038/s41574-021-00551-9
26. Khadilkar SS. Musculoskeletal disorders and menopause. *J Obstet Gynaecol India*. 2019;69(2):99–103. PMID: 30956461; PMCID: PMC6430266. doi:10.1007/s13224-019-01213-7
27. Cho EJ, Choi Y, Jung SJ, Kwak HB. Role of exercise in estrogen deficiency-induced sarcopenia. *J Exerc Rehabil*. 2022;18(1):2–9. PMID: 35356136; PMCID: PMC8934617. doi:10.12965/jer.2244004.002
28. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing group for the European working group on sarcopenia in older people 2 (EWGSOP2), and the extended group for EWGSOP2. *Sarcopenia*. 2019;48(1):16–31. PMID: 31081853; PMCID: PMC6593317. doi:10.1093/ageing/afy169
29. Yu M, Pan M, Liang Y, Li X, Li J, Luo L. A nomogram for screening sarcopenia in Chinese type 2 diabetes mellitus patients. *Exp Gerontol*. 2023;172:112069. PMID: 36535452. doi:10.1016/j.exger.2022.112069
30. He X, Song Y, Ma L, Ainsworth BE, Liu Y, Chen N. Prevalence and factors influencing sarcopenia among community-dwelling older adults using the asian working group for sarcopenia definition. *Clin Interv Aging*. 2022;17:1707–1727. PMID: 36471806; PMCID: PMC9719269. doi:10.2147/CIA.S388319
31. Yu R, Wong M, Leung J, Lee J, Auyeung TW, Woo J. Incidence, reversibility, risk factors and the protective effect of high body mass index against sarcopenia in community-dwelling older Chinese adults. *Geriatr Gerontol Int*. 2014;14(Suppl 1):15–28. PMID: 24450557. doi:10.1111/ggi.12220
32. Li S, Huang L, Wang L. Effects of 12 weeks aerobic exercise combined with high speed strength training on old adults with osteo- sarcopenic obesity syndrome. *Chin J Rehabil Med*. 2020;35:420–426. doi:10.3969/j.issn.1001-1242.2020.04.007
33. Pacifico L, Perla FM, Chiesa C. Sarcopenia and nonalcoholic fatty liver disease: a causal relationship. *Hepatobiliary Surg Nutr*. 2019;8(2):144–147. PMID: 31098363; PMCID: PMC6503235. doi:10.21037/hbsn.2018.11.11

34. Li C, Kang B, Zhang T, et al. High visceral fat area attenuated the negative association between high body mass index and sarcopenia in community-dwelling older Chinese people. *Healthcare*. 2020;8(4):479. PMID: 33198340; PMCID: PMC7712146. doi:10.3390/healthcare8040479
35. Yoo MC, Won CW, Soh Y. Association of high body mass index, waist circumference, and body fat percentage with sarcopenia in older women. *BMC Geriatr*. 2022;22(1):937. PMID: 36471279; PMCID: PMC9724283. doi:10.1186/s12877-022-03643-x
36. Choi S, Chon J, Lee SA, et al. Central obesity is associated with lower prevalence of sarcopenia in older women, but not in men: a cross-sectional study. *BMC Geriatr*. 2022;22(1):406. PMID: 35534812; PMCID: PMC9082840. doi:10.1186/s12877-022-03102-7
37. Kim TN, Park MS, Yang SJ, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). *Diabetes Care*. 2010;33(7):1497–1499. PMID: 20413515; PMCID: PMC2890348. doi:10.2337/dc09-2310
38. Hung J, McQuillan BM, Thompson PL, Beilby JP. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. *Int J Obes Lond*. 2008;32(5):772–779. PMID: 18253163. doi:10.1038/sj.ijo.0803793
39. Wang J, Liu C, Zhang L, et al. Prevalence and associated factors of possible sarcopenia and sarcopenia: findings from a Chinese community-dwelling old adults cross-sectional study. *BMC Geriatr*. 2022;22(1):592. PMID: 35850661; PMCID: PMC9290196. doi:10.1186/s12877-022-03286-y

Diabetes, Metabolic Syndrome and Obesity

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal>